文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植后CMV再激活的治疗策略

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood · 2020-01-01

异基因造血干细胞移植后CMV再激活仍是常见且危及生命的感染并发症。治疗决策需综合抗病毒预防史、个体CMV疾病风险、CMV特异性T细胞重建、病毒载量及耐药检测,推动个体化治疗策略。

要点

  • 治疗前需确认是否用过抗CMV预防,并评估个体CMV疾病风险。
  • CMV特异性T细胞免疫与病毒载量应纳入治疗决策。
  • 启动抗病毒治疗时需考虑潜在耐药,实施个体化策略。

核心结论

  • 基于预防史、病毒载量、CMV特异性T细胞免疫及耐药分子评估的个体化策略正日益用于CMV再激活的移植受者。

主要发现

  • 尽管有新型诊断技术、新型预防药物及抢先治疗改进,CMV再激活仍是异基因造血干细胞移植后常见且危及生命的感染并发症。

临床怎么用

  • 治疗决策需考虑患者是否接受过抗病毒预防、个体CMV疾病风险、CMV特异性T细胞重建、CMV病毒载量及启动治疗时检测的潜在耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult and must take into account whether the patient has received antiviral prophylaxis, the patient's individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detected at the time of initiation of antiviral therapy. Thus, we increasingly use personalized treatment strategies for the recipient of an allograft with CMV reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistance to antiviral drugs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Einsele H, Ljungman P, Boeckh M, et al. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020. PMID: 32202631. doi:10.1182/blood.2019000956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。